Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Mephenoxalone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | SYK | P43405 | 8/20 | 0.56 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mephenoxalone SCHEMBL6492968 | 0.96 | PKM (0.73) | PKMSYKIRAK4ADRA2CLMNA | |
| Mephenoxalone SCHEMBL935967 | 0.96 | PKM (0.77) | PKMSYKIRAK4ADRA2CLMNA | |
| Mephenoxalone SCHEMBL5392 | 0.96 | PKM (0.77) | PKMSYKIRAK4ADRA2CLMNA | |
| Mephenoxalone SCHEMBL4621926 | 0.96 | PKM (0.77) | PKMSYKIRAK4ADRA2CLMNA | |
| Mephenoxalone SCHEMBL2175454 | 0.95 | PKM (0.75) | PKMSYKIRAK4ADRA2CLMNA | |
| Mephenoxalone SCHEMBL7938104 | 0.95 | PKM (0.75) | PKMSYKIRAK4ADRA2CLMNA | |
| Mephenoxalone SCHEMBL6098064 | 0.95 | PKM (0.75) | PKMSYKIRAK4ADRA2CLMNA | |
| Mephenoxalone SCHEMBL7117835 | 0.95 | PKM (0.75) | PKMSYKIRAK4ADRA2CLMNA | |
| Mephenoxalone SCHEMBL22472152 | 0.95 | PKM (0.75) | PKMSYKIRAK4ADRA2CLMNA | |
| Mephenoxalone SCHEMBL1061349 | 0.95 | PKM (0.75) | PKMSYKIRAK4ADRA2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016126572-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-08-11 | — | — | WO | claimed |
| US-8729269-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2014-05-20 | — | — | US | disclosed |
| US-20100144735-A1 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | WOCKHARDT LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-7687627-B2 | Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy | WOCKHARDT LIMITED (IN) | 2010-03-30 | — | — | US | disclosed |
| US-20080119419-A1 | Bifunctional heterocyclic compounds and methods of making and using same | BioVersys AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-7335753-B2 | Bifunctional heterocyclic compounds and methods of making and using same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1114819-B1 | Process to prepare oxazolidinones | PHARMACIA & UPJOHN CO LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20060264385-A1 | Bifunctional heterocyclic compounds and methods of making and using same | BioVersys AG (CH) | 2006-11-23 | — | — | US | disclosed |
| US-7091196-B2 | Bifunctional heterocyclic compounds and methods of making and using same | RIB-X PHARMACEUTICALS, INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1664038-A2 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED I IN VIVO /I EFFICACY | Wockhardt Limited (IN) | 2006-06-07 | — | — | EP | disclosed |
| WO-1997037980-A1 | PROCESS TO PREPARE OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 1997-10-16 | — | — | WO | disclosed |
| US-5654435-A | BACTERICIDES | PHARMACIA & UPJOHN COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| US-5654428-A | BACTERICIDES | PHARMACIA & UPJOHN COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0610265-B1 | SUBSTITUTED ARYL- AND HETEROARYLPHENYLOXAZOLIDINONES USEFUL AS ANTIBACTERIAL AGENTS | UPJOHN CO (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5565571-A | BACTERICIDES | THE UPJOHN COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| US-5523403-A | Tropone-substituted phenyloxazolidinone antibacterial agents | THE UPJOHN COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0673370-A1 | TROPONE-SUBSTITUTED PHENYLOXAZOLIDINONE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1995-09-27 | — | — | EP | disclosed |
| EP-0610265-A1 | SUBSTITUTED ARYL- AND HETEROARYLPHENYLOXAZOLIDINONES USEFUL AS ANTIBACTERIAL AGENTS. | UPJOHN CO (US) | 1994-08-17 | — | — | EP | disclosed |
| WO-1994013649-A1 | TROPONE-SUBSTITUTED PHENYLOXAZOLIDINONE ANTIBACTERIAL AGENTS | THE UPJOHN COMPANY (US) | 1994-06-23 | — | — | WO | disclosed |
| WO-1993009103-A1 | SUBSTITUTED ARYL- AND HETEROARYLPHENYLOXAZOLIDINONES USEFUL AS ANTIBACTERIAL AGENTS | THE UPJOHN COMPANY (US) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119419-A1 | Bifunctional heterocyclic compounds and methods of making and using same | PCNA, DCX, ATIC | PKM 2790/4885SYK 4526/4885IRAK4 3092/4885 |
| US-20060264385-A1 | Bifunctional heterocyclic compounds and methods of making and using same | PCNA, DCX, ATIC | PKM 2790/4885SYK 4526/4885IRAK4 3092/4885 |
| US-20100144735-A1 | SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY | GMPS, MPO, ARG1 | PKM 1060/4885SYK 773/4885IRAK4 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.